Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever?

被引:0
|
作者
Erden, A. [1 ]
Batu, E. D. [2 ]
Sari, A. [1 ]
Sonmez, H. E. [2 ]
Armagan, B. [1 ]
Demir, S. [2 ]
Firat, E. [3 ]
Bilginer, Y. [2 ]
Bilgen, S. A. [1 ]
Karadag, O. [1 ]
Kalyoncu, U. [1 ]
Kiraz, S. [1 ]
Ertenli, I. [1 ]
Ozen, S. [2 ]
Akdogan, A. [1 ]
机构
[1] Hacettepe Univ, Div Rheumatol, Dept Internal Med, Fac Med, Ankara, Turkey
[2] Hacettepe Univ, Div Rheumatol, Dept Paediat, Fac Med, TR-06100 Ankara, Turkey
[3] Hacettepe Univ, Dept Internal Med, Fac Med, Ankara, Turkey
关键词
familial Mediterranean fever; colchicine resistance; colchicine unresponsiveness; RECOMMENDATIONS; ASSOCIATION; MANAGEMENT; DIAGNOSIS; ANAKINRA; CRITERIA; CHILDREN; SCORE; FMF;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Colchicine is the main therapy for familial Mediterranean fever (FMF); however, 5-10% of patients are colchicine-resistant. There is no standard and validated definition for colchicine resistance. We aimed to compare the existing definitions for colchicine resistance in both adult and paediatric FMF patients to find out the best definition to determine colchicine-resistant patients. Methods. 385 FMF patients were evaluated and patients receiving antiinterleukin-1 treatment were included. The anti-IL-1 therapy had been initiated by the experts in the past based on their experience. Eleven different definitions (found out after PubMed search for colchicine resistance in FMF) were applied to all patients. Results were re-analysed after excluding the patients who had no clinical attacks but persistently high acute phase reactants (APRs) and/or amyloidosis. Results. Sixty patients (40 adults/20 children) who had been using anti-IL-1 therapy were included into this study as colchicine-resistant patients. The highest percentage of patients fulfilled definition 5 (93.3%). Definition 9 had the poorest performance (26%). Significantly, a higher percentage of adult patients met definitions 4 and 6 than paediatric patients (87.5% vs. 50%, p= O. O02; 75% vs. 40%, p= O. O08, respectively). After excluding patients without clinical attacks, the highest percentage of patients fulfilled definition 2 (94.4%). We combined the attack frequency (> 1 typical episode/3 months) in definition 2 and presence of amyloidosis/APR increase (increase in ! 2/3 APRs) in definition 5 to create a new definition which was met by 59 (98.3%) colchicine-resistantF MF patients. Conclusion. Definition of colchicine resistance is still controversial. Definitions with both clinical and laboratory criteria were met by a higher percentage of resistant patients than those without laboratory criteria. However, the proper definitions for the attack-free period and persistence of APRs are still lacking.
引用
收藏
页码:S97 / S102
页数:6
相关论文
共 50 条
  • [41] The Effect of Clinical and Genetic Variables of Familial Mediterranean Fever Patients: Real Life Data
    Oner, Nimet
    Celikel, Elif
    Gungorer, Vildan
    Tekin, Zahide Ekici
    Coskun, Serkan
    Karagol, Cuneyt
    Sezer, Muge
    Tekgoz, Nilufer
    Kaplan, Melike Mehves
    Polat, Merve Cansu
    Acar, Banu Celikel
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 (07) : 326 - 331
  • [42] Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine
    Lidar, M
    Kedem, R
    Langevitz, P
    Pras, M
    Livneh, A
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (12) : 2620 - 2623
  • [43] Discontinuation of Colchicine Therapy in Children With Familial Mediterranean Fever
    Aviel, Yonatan Butbul
    Rawan, Silman
    Fahoum, Shafe
    Wexler, Isaiah
    Berkun, Yackov
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (11) : 1732 - 1735
  • [44] Comparison of patients with familial Mediterranean fever accompanied with sacroiliitis and patients with juvenile spondyloarthropathy
    Sonmez, H. E.
    Batu, E. D.
    Demir, S.
    Bilginer, Y.
    Ozen, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (06) : S124 - S127
  • [45] Colchicine enhances intestinal permeability in patients with familial Mediterranean fever
    Fradkin, A
    Yahav, J
    DiverHaber, A
    Zemer, D
    Jonas, A
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (3-4) : 241 - 245
  • [46] The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever
    Lorenzo Calligaris
    Federico Marchetti
    Alberto Tommasini
    Alessandro Ventura
    European Journal of Pediatrics, 2008, 167 : 695 - 696
  • [47] Colchicine in tear fluid of treated patients with familial Mediterranean fever
    Leibovitch, I
    Alster, Y
    Scherrmann, JM
    Azmon, B
    Barequet, IS
    Livneh, A
    O'Brien, TP
    Lazar, M
    Loewenstein, A
    CORNEA, 2003, 22 (03) : 191 - 193
  • [48] Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
    Sahin, Ali
    Derin, Mehmet Emin
    Albayrak, Fatih
    Karakas, Burak
    Karagoz, Yalcin
    ADVANCES IN RHEUMATOLOGY, 2020, 60 (01)
  • [49] Canakinumab Treatment in Familial Mediterranean Fever Patients: With/Without Colchicine
    Ogut, Tahir Saygin
    Yazisiz, Veli
    Dilbil, Melis
    Nokay, Mine
    Terzioglu, Mustafa Ender
    Erbasan, Funda
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2025, 28 (03)
  • [50] Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents
    Eroglu, Fehime Kara
    Besbas, Nesrin
    Topaloglu, Rezan
    Ozen, Seza
    RHEUMATOLOGY INTERNATIONAL, 2015, 35 (10) : 1733 - 1737